Biotech entity
U.S. FDA is most often covered alongside FBD Biologics Limited, which appears in 1 of these 2 stories. That works out to roughly 0.1 stories per week across a 130-day span. Each story carries 2.5 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
U.S. FDA is most often covered alongside FBD Biologics Limited, which appears in 1 of these 2 stories. That works out to roughly 0.1 stories per week across a 130-day span. Each story carries 2.5 original sources on average, compared with 3.6 for the broader beat in this window. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. At 7, the average consequence score sits above the same-window beat average of 6.2. This profile follows 2 Biotech stories mentioning U.S. FDA across the period from March 5, 2026 to July 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 397 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. FDA. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Anticipated preliminary safety and pharmacokinetic results from Phase I.
Trial Initiation
Expected commencement of patient recruitment and site activation.
FDA IND Approval
GNTbm receives official clearance to begin Phase I trials for GNTbm-38.
In a preclinical MOU, HanchorBio will evaluate its CD47/SIRPα asset HCB101 alongside InxMed’s ifebemtinib and OMTX705. The partnership signals a strategic pivot toward using HCB101 as a combination backbone, potentially de-risking the single-indication pipeline and differentiating the asset in a tricky class.
Source: manilatimes.net · prnewswire.com
GNTbm has received Investigational New Drug (IND) approval from the U.S. FDA to initiate Phase I clinical trials for its self-developed anti-cancer therapy, GNTbm-38. This milestone marks the company's formal entry into the U.S. clinical landscape, targeting advanced malignancies with its proprietary therapeutic candidate.
U.S. FDA is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
